Locus Biosciences, Inc. is a biotechnology company that develops precision, engineered bacteriophage products. Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology. The LOCUS platform combines predictive artificial intelligence and automated robotics to deliver optimized precision phage therapies that specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unaffected. Locus has strong backing from partners, having signed contracts with BARDA and CARB-X. The company recently completed the open-label portion of a Phase 2 trial assessing LBP-EC01 for the treatment of uncomplicated …

35 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting Chronic Pain Algonist Biotechnologies is a pre-clinical stage biotechnology company, developing novel small molecule therapeutics for chronic pain. Our mission is to develop drugs with similar potency to opioids but without leading to addiction.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Securing your vision Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea, such as keratoconus, glaucoma and corneal transplants.

84 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

195 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing the storage and delivery of vaccines and therapeutics. We are a biotechnology company revolutionizing vaccines and biologics by removing all cold storage requirements and expediting manufacturing.

83 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

At Bioharmony Therapeutics, we are developing nontraditional antimicrobial therapeutics by exploiting millions of years of phage-bacteria evolution. Our focus is on targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria. Our primary therapeutic indication is for Acinetobacter baumannii skin and wound infections.

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a …

26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better materials for better products Lygos is a pioneering sustainable specialty chemicals company, leading the world’s transition toward better, cleaner, and more sustainable products. We have built a proprietary and fully integrated platform of the most advanced technologies across synthetic biology, industrial chemistry, and application development to rapidly deliver market relevant solutions to some of the world’s biggest sustainability challenges. With a pipeline of high-performing, innovative solutions, Lygos is paving the way for generations of new sustainable solutions for our world. Synthetic Biology and Specialty Chemicals

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical CRISPR and Gene Therapy of the Microbiome Company We are the CRISPR and Gene Therapy of the Microbiome company! Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota. Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating Drugs at the Speed of Ai Absci is a data-first AI drug creation company designing differentiated therapeutics using generative AI. Our Integrated Drug Creation platform powers cutting-edge de novo AI models and AI lead optimization models aimed at designing better biologics against difficult-to-drug targets. generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology

80 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning Generative A.I. Synthetic Biology

Designing novel proteins, enzymes, and antibodies is limited by the problem of generating and screening vast mutational sequence space. Revolve addresses this problem with our patented library generation platform producing custom DNA libraries with unparalleled efficiency. The company has developed an ultra-affinity antibody discovery engine based on this library platform and has a pipeline of protein products in development. Custom mutagenesis libraries, Protein Engineering, Protein Libraries, and Antibody Engineering

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Using circular RNA to control any gene, in any species, in any cell type. "Acquired by Ginkgo Bioworks in 2022" Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence. Gene Expression, Bioprocessing, Molecular Biology, Protein Expression, Drug Discovery, …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing new treatments to patients faster and more efficiently. Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

178 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Solving for today. Building for tomorrow. BIOTECanada is the national industry association voice. With over 230 member companies, the Association’s membership is representative of the broader Canadian biotech ecosystem which is national in scope and comprised of pre-commercial biotech companies, global pharma and biotech companies, investors, incubator and accelerator organizations, and academia. In the context of global population growth and corresponding climate change, food sustainability, and human health needs, the biotechnology industry plays a vital role in developing solutions to help address the resulting human health and environmental challenges.

78 similar entities Type: SMB Activities: deeptech biotech Technologies: Decarbonization

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Botulinum Toxin, biotechnology, biotech, healthcare, pharmaceuticals, science, research, financial services, and fintech

354 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The leading international supplier to the microbiology and tissue culture industries Don Whitley Scientific is a leading international supplier of innovative equipment and services to the microbiology and tissue culture industries. We develop, manufacture, market and service instrumentation and associated products for the public and private sector - primarily for use in hospitals, public health laboratories, food testing organisations and research institutions. We now have the largest, most comprehensive range of workstations specifically designed for the study of anaerobes and microaerophiles. Automated microbiology and cell culture equipment, Contract microbiology laboratory, and Service and maintenance contracts

116 similar entities Type: SMB Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Developing #biobasedValue Biocatalysts is a biotechnology company producing speciality enzymes at commercial scales for a variety of industries. Biocatalysts has used its wide range of technical, commercial and regulatory capabilities to develop #BiobasedValue for our customers. Established in 1983, Biocatalysts has been a member of the international BRAIN Group since 2018. Next to first-class research and development services for industry customers to create bio-based products and processes, the Group distributes specialty ingredients, like enzymes or bioactive natural products. Own fermentation and production facilities in Continental Europe, UK and the US, together with the associated biotechnological solution competency complete the value …

87 similar entities Type: SMB Activities: biotech deeptech Technologies: Bio sourced materials

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

142 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices …

151 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing healthcare through innovative adenosine receptor-based drugs Palobiofarma S.L. is a Spanish biopharmaceutical company dedicated to discovering and developing innovative drugs based on the modulation of adenosine receptors.

226 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties. R&D-wise, GeneCode has remarkably improved the properties of the identified hits, making them more active and effective, drug-like and better show their ability to combat neurodegeneration in Parkinson ́s disease (PD).

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Dairy Done Differently Imagindairy, a Foodtech company, is addressing the industry bottleneck by integrating deep tech with system biology to develop a commercial and viable animal free protein-based dairy product

93 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Molecular Tools and Laboratory Essentials Since its founding in 1992, bioWORLD has established, maintained, and succeeded in its core mission to manufacture and supply high-quality molecular tools, biological reagents, and laboratory supplies to analytical laboratories, academia institutions, and research corporations globally. bioWORLD specializes in numerous product lines for the Life Sciences and Biotechnology industries. With product focuses including bioAffinity reagents for protein purification and proteomics research, recombinant proteins and synthetic peptides, plant, microbiological, animal, and yeast media, and many other fields. In addition, bioWORLD offers services including custom peptide synthesis and antibody production. The company's headquarters are in Dublin, Ohio, …

62 similar entities Type: SMB Activities: manufacturing Technologies: Synthetic Biology

We care about everybody's health Arterra Bioscience is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various industrial sectors. Arterra is a company strongly linked to the Campania region from which it derives the natural raw materials underlying many of its actives, as well as being able to take advantage of the ideas and enthusiasm of its young researchers. Biotechnology, R&D, Cosmetics, medical Device, Agriculture, and Agrifood

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology